Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Accumulated Expenses (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Accumulated Expenses for 11 consecutive years, with $16.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Expenses changed N/A to $16.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $16.3 million, a N/A change, with the full-year FY2025 number at $16.3 million, changed N/A from a year prior.
  • Accumulated Expenses was $16.3 million for Q4 2025 at Crescent Biopharma, up from $7.6 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $16.3 million in Q4 2025 to a low of $399763.0 in Q4 2023.
  • A 5-year average of $3.9 million and a median of $2.1 million in 2021 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: tumbled 94.28% in 2023, then soared 1294.56% in 2025.
  • Crescent Biopharma's Accumulated Expenses stood at $2.2 million in 2021, then skyrocketed by 224.86% to $7.0 million in 2022, then crashed by 94.28% to $399763.0 in 2023, then soared by 770.0% to $3.5 million in 2024, then skyrocketed by 369.93% to $16.3 million in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Accumulated Expenses are $16.3 million (Q4 2025), $7.6 million (Q2 2025), and $2.5 million (Q1 2025).